Plant-derived withaferin A drives two cell-death routes in gastric cancer models
- A withanolide from Withania somnifera was tested in gastric cancer cells, where it curbed growth and migration.
- It triggered ROS-driven mitochondrial injury and shifted apoptosis regulators toward cell death, while also promoting ubiquitin-mediated loss of GPX4 and engaging Keap1/Nrf2/HO-1 signalling to cause lipid peroxidation and iron buildup.
- In a mouse xenograft the compound slowed tumours without obvious systemic toxicity.
💡 Points Based on the abstract
Withaferin A is a notoriously promiscuous electrophile, so "hits Keap1/Nrf2 and GPX4" mostly reads as covalent reactivity, not a validated target. ROS-driven killing in cell lines and a xenograft with "no obvious toxicity" say nothing about free exposure at the efficacious dose or the safety margin. Show tumour drug levels and a thiol-reactivity control before any follow-up.